7775 DAIKEN MEDICAL CO.,LTD. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

7775

TSE Standard

DAIKEN MEDICAL CO.,LTD.

439

JPY

(0.00%)

Dec 12, 3:30 pm JST

2.81

USD

Dec 12, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	8,540	1,150	1,152	831	28.9	20	May 13, 2022	J-GAAP
Mar, 2023	9,137	1,054	1,053	712	24.8	20	May 15, 2023	J-GAAP
Mar, 2024	9,750	1,442	1,450	988	34.4	21	May 15, 2024	J-GAAP
Mar, 2025	9,951	1,512	1,510	1,097	38.2	23	May 15, 2025	J-GAAP
Mar, 2026 Guidance	10,500	1,010	1,000	700	24.4	20	May 15, 2025	J-GAAP
YoY	+5.5%	-33.2%	-33.8%	-36.2%	-36.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 15, 2020	ー	ー	ー	ー	－	J-GAAP
- - - - -	Jul 31, 2020	8,400	1,160	1,200	860	20	J-GAAP
	Jan 29, 2021	8,000	960	1,000	710	20	J-GAAP
Results	May 14, 2021	7,861	921	957	675	20	J-GAAP
Mar, 2022	May 14, 2021	Available in future release
	Oct 29, 2021
Results	May 13, 2022
Mar, 2023	May 13, 2022
	Oct 31, 2022
	Apr 28, 2023
Results	May 15, 2023
Mar, 2024	May 15, 2023
	Jan 31, 2024
Results	May 15, 2024
Mar, 2025	May 15, 2024
Results	May 15, 2025
Mar, 2026	May 15, 2025	10,500	1,010	1,000	700	20	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2004	3,310	－	Available in future release
Mar, 2005	3,519	+6.3
Mar, 2006	3,789	+7.7
Mar, 2007	4,186	+10.5
Mar, 2008	4,608	+10.1
Mar, 2009	5,181	+12.4
Mar, 2010	5,739	+10.8
Mar, 2011	6,242	+8.8
Mar, 2012	6,515	+4.4
Mar, 2013	7,068	+8.5
Mar, 2014	7,635	+8.0
Mar, 2015	8,033	+5.2
Mar, 2016	8,261	+2.8
Mar, 2017	8,399	+1.7
Mar, 2018	8,585	+2.2
Mar, 2019	8,406	-2.1
Mar, 2020	8,523	+1.4
Mar, 2021	7,861	-7.8
Mar, 2022	8,540	+8.6
Mar, 2023	9,137	+7.0
Mar, 2024	9,750	+6.7
Mar, 2025	9,951	+2.1
Mar, 2026 Guidance	10,500	+5.5	1,010	-33.2	1,000	-33.8	24.4	-36.1

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	9,750	1,442	14.8	14.57	8.97	0.89	34.4
Mar, 2025	9,951	1,512	15.2	15.16	9.89	0.90	38.2
Mar, 2026 Guidance	10,500	1,010	9.62	9.22	6.46	0.97	24.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	9,951	1,711	1,714	1,246	41.6
Fiscal Year	Mar, 2025	Mar, 2017	Mar, 2017	Mar, 2017	Mar, 2017

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	4,683	449	448	283	9.9	11	May 15, 2023	J-GAAP
Oct - Mar, 2023	4,926	697	700	451	15.7	12	May 15, 2024	J-GAAP
Oct - Mar, 2024	5,037	676	674	489	17.0	14	May 15, 2025	J-GAAP
Oct - Mar, 2025 Guidance	5,443	334	326	189	6.6	11	Oct 31, 2025	J-GAAP
YoY	+8.1%	-50.6%	-51.6%	-61.3%	-61.4%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	1,054	779	989	-210	-781	2,516	22.85	J-GAAP
Mar, 2024	1,442	1,387	1,555	-168	-1,163	2,739	24.89	J-GAAP
Mar, 2025	1,512	952	1,120	-168	-696	2,995	26.79	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2023	4,824	745	750	537	18.7	51.7	Oct 31, 2023	J-GAAP
Apr - Sep, 2024	4,914	836	836	608	21.2	55.4	Oct 31, 2024	J-GAAP
Apr - Sep, 2025	5,057	676	674	511	17.8	67.4	Oct 31, 2025	J-GAAP
YoY	+2.9%	-19.1%	-19.4%	-16.0%	-15.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	2,582	492	492	351	12.2	19.1	Jan 31, 2024	J-GAAP
Jan - Mar, 2024	2,344	205	208	100	3.5	8.7	May 15, 2024	J-GAAP
Apr - Jun, 2024	2,395	397	398	289	10.1	16.6	Jul 31, 2024	J-GAAP
Jul - Sep, 2024	2,519	439	438	319	11.1	17.4	Oct 31, 2024	J-GAAP
Oct - Dec, 2024	2,751	479	479	349	12.2	17.4	Jan 31, 2025	J-GAAP
Jan - Mar, 2025	2,286	197	195	140	4.9	8.6	May 15, 2025	J-GAAP
Apr - Jun, 2025	2,497	281	282	215	7.5	11.3	Jul 31, 2025	J-GAAP
Jul - Sep, 2025	2,560	395	392	296	10.3	15.4	Oct 31, 2025	J-GAAP
YoY	+1.6%	-10.0%	-10.5%	-7.2%	-7.2%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2020	2,244	-0.4	Available in future release
Jan - Mar, 2021	1,846	-8.7
Apr - Jun, 2021	1,977	+10.4
Jul - Sep, 2021	2,109	+6.5
Oct - Dec, 2021	2,334	+4.0
Jan - Mar, 2022	2,120	+14.8
Apr - Jun, 2022	2,196	+11.1
Jul - Sep, 2022	2,258	+7.1
Oct - Dec, 2022	2,442	+4.6
Jan - Mar, 2023	2,241	+5.7
Apr - Jun, 2023	2,361	+7.5
Jul - Sep, 2023	2,463	+9.1
Oct - Dec, 2023	2,582	+5.7
Jan - Mar, 2024	2,344	+4.6
Apr - Jun, 2024	2,395	+1.4
Jul - Sep, 2024	2,519	+2.3
Oct - Dec, 2024	2,751	+6.5
Jan - Mar, 2025	2,286	-2.5
Apr - Jun, 2025	2,497	+4.3
Jul - Sep, 2025	2,560	+1.6	395	-10.0	392	-10.5	10.3	-7.2

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	2,751	501	501	364	12.2
Fiscal Year	Dec, 2024	Dec, 2015	Dec, 2015	Dec, 2016	Dec, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	228.91	59.7	11,013	6,576	7,506	0.41	May 15, 2023	J-GAAP
Mar, 2024	243.32	63.5	11,006	6,990	7,920	0.30	May 15, 2024	J-GAAP
Mar, 2025	260.53	66.9	11,181	7,484	8,414	0.27	May 15, 2025	J-GAAP
Apr - Sep, 2025	ー	70.1	10,828	7,594	8,524	0.22	Oct 31, 2025	J-GAAP

DAIKEN MEDICAL CO.,LTD.(7775) Financial Results